Mixed chimerism in haemoglobinopathies: From risk of graft rejection to immune tolerance

Tissue Antigens

Volumn 83, Issue 3, 2014, Pages 137-146

  Andreani, M ^a   Testi, M ^a   Lucarelli, G ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Beta thalassemia; Immune tolerance; Mixed chimerism

Indexed keywords

BETA THALASSEMIA; IMMUNE TOLERANCE; MIXED CHIMERISM;

CHIMERISM; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHIES; HUMANS; IMMUNE TOLERANCE; RISK FACTORS;

EID: 84894269854     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12313     Document Type: Review

References (73)

1. Thomas ED, Buckner CD, Banaji M et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977: 49: 511-33.
2. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983: 309: 1347-53.
3. Gaziev J, Sodani P, Polchi P, Andreani M, Lucarelli G. Bone marrow transplantation in adults with thalassemia. Treatment and longterm follow-up. Ann NY Acad Sci 2005: 1054: 196-205.
4. Lucarelli G, Clift R, Galimberti M et al. Marrow transplantation for patients with thalassemia: results in Class 3 patients. Blood 1996: 87: 2082-8.
5. Sodani P, Gaziev J, Polchi P et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17years. Blood 2004: 104: 1201-3.
6. Angelucci E. Hematopoietic stem cell transplantation in thalassemia. Hematology Am Soc Hematol Educ Program 2010: 2010: 456-62. doi: 10.1182/asheducation-2010.1.456.
7. Locatelli F, De Stefano P. Innovative approaches to hematopoietic stem cell transplantation for patients with thalassemia. Haematologica 2005: 90: 1592-4.
8. La Nasa G, Giardini C, Argiolu F et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002: 99: 4350-6.
9. Di Bartolomeo P, Santarone S, Di Bartolomeo E et al. Long-term results of bone marrow transplantation for thalassemia major in Pescara. Blood 2004: 104: 3332-7.
10. Lucarelli G, Isgrò A, Sodani P, Gaziev J. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med 2012: 2: a11825.
11. Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012: 4: 2807-16.
12. Appelbaum FR. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia. Best Pract Res Clin Haematol 2013: 26: 279-84.
13. Aristei C, Santucci A, Corvò R et al. In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study. Italian TBI Working Group. Bone Marrow Transplant 2013: 48: 908-14.
14. Ruutu T, Gratwohl A, de Witte T et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014: 49: 31-5. doi: 10.1038/bmt.2013.210.
15. Devine SM, Carter S, Soiffer RJ et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: Results of the Blood and Marrow Transplant Clinical Trials Network protocol 0303. Biol Blood Marrow Transplant 2011: 17: 1343-51.
16. Kumar AJ, Hexner EO, Frey NV et al. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013: 19: 1094-101.
17. Giebel S, Labopin M, Mohty M et al. The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant 2013: 48: 238-42.
18. Andreani M, Nesci S, Lucarelli G et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000: 25: 401-4.
19. Andreani M, Testi M, Battarra M et al. G. Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. Blood Transfus 2008: 6: 143-9.
20. Sachs DH, Sykes M, Kawai T, Cosimi AB. Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol 2011: 23: 165-73.
21. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997: 89: 3048-54.
22. Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008: 358: 353-61.
23. Spitzer TR, Sykes M, Tolkoff-Rubin N et al. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011: 91: 672-6.
24. Sachs DH, Kawai T, Sykes M. Induction of tolerance through mixed chimerism. Cold Spring Harb Perspect Med 2014: 4. pii: a015529. doi: 0.1101/cshperspect.a015529.
25. Cobbold SP, Castejon R, Adams E et al. Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004: 172: 6003-10.
26. Tippet P. Blood group chimeras. Vox Sang 1983: 44: 333-59.
27. McCann SR, Lawler M. Mixed chimerism; detection and significance following BMT. Bone Marrow Transplant 1993: 11: 91-4.
28. Lawler SD, Harris H, Millar J, Barrett A, Powles RL. Cytogenetic follow-up studies of recipients of T-cell depleted allogeneic bone marrow. Br J Haematol 1987: 65: 143-50.
29. Dewald G, Stallard R, Al Saadi A et al. A multicenter investigation with interphase fluorescence in situ hybridization using X- and Y-chromosome probes. Am J Med Genet 1998: 76: 318-26.
30. Thiede C, Florek M, Bornhauser M et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999: 23: 1055-60.
31. Bader P, Holle W, Klingebiel T, Handgretinger R, Niethammer D, Beck J. Quantitative assessment of mixed hematopoietic chimerism by polymerase chain reaction after allogeneic BMT. Anticancer Res 1996: 16: 1759-63.
32. Thiede C, Bornhauser M, Oelschlagel U et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 2001: 15: 293-302.
33. Alizadeh M, Bernard M, Danic B et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002: 99: 4618-25.
34. Mazzi B, Clerici TD, Zanussi M et al. Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. Leukemia 2008: 22: 2119-22.
35. Vago L, Perna SK, Zanussi M et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009: 361: 478-88.
36. Andreani M, Testi M, Gaziev J et al. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica 2011: 96: 128-33.
37. Andreani M, Testi M, Battarra M, Lucarelli G. Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies. Chimerism 2011: 2: 21-2.
38. Lion T, Watzinger F, Preuner S et al. The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia 2012: 26: 1821-8.
39. Bader P, Kreyenberg H, Hoelle W et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004: 33: 815-21.
40. Serrano J, Roman J, Sanchez J et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210BCR-ABL and p190BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190BCR-ABL detection precede cytogenetic relapse. Blood 2000: 95: 2659-65.
41. Bacigalupo A, Ballen K, Rizzo D et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009: 15: 1628-33.
42. Shimoni A, Nagler A. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. Best Pract Res Clin Haematol 2011: 24: 369-79.
43. Bacher U, Haferlach T, Fehse1 B, Schnittger S, Kröger N. Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia. Scientific World Journal 2011: 11: 310-9.
44. Mossallam GI, Kamel AM, Storer B, Martin PJ. Prognostic utility of routine chimerism testing at 2 to 6months after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009: 15: 352-9.
45. Waterhouse M, Bertz H, Finke J. A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1, and FLT3-ITD mutations after allogeneic stem cell transplantation. Ann Hematol 2014: 93: 293-8 doi: 10.1007/s00277-013-1858-2. Epub 2 August 2013.
46. Lion T. Detection of impending graft rejection and relapse by lineage-specific chimerism analysis. Methods Mol Med 2007: 134: 197-216.
47. Goh RY, Kim SH, Han JY. Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation. Korean J Hematol 2011: 46: 18-23.
48. Moratto D, Giliani S, Bonfim C et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011: 118: 1675-84.
49. Antin JH, Childs R, Filipovich AH et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2001: 7: 473-85.
50. Urbano-Ispizua A, Rozman C, Pimentel P et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001: 97: 383-7.
51. Bornhauser M, Oelschlaegel U, Platzbecker U et al. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 2009: 94: 1613-7.
52. Rosenow F, Berkemeier A, Krug U et al. CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT. Bone Marrow Transplant 2013: 48: 1070-6.
53. Andreani M, Manna M, Lucarelli G et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996: 87: 3494-9.
54. Smeets D, Hoogenhout J, Haanen C. Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. Blood 1989: 73: 1367-70.
55. Breuer S, Preuner S, Fritsch G et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia 2012: 26: 509-19.
56. Nesci S, Manna M, Lucarelli G et al. Mixed chimerism after bone marrow transplantation in thalassemia. Ann N Y Acad Sci 1998: 850: 495-7.
57. Lisini D, Zecca M, Giorgiani G et al. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling. Haematologica 2008: 93: 1859-67.
58. Manna M, Nesci S, Andreani M, Tonucci P, Lucarelli G. Influence of the conditioning regimens on the incidence of mixed chimerism in thalassemic transplanted patients. Bone Marrow Transplant 1993: 12 (Suppl 1): 70-3.
59. Gammill HS, Adams Waldorf KM, Aydelotte TM et al. Pregnancy, microchimerism, and the maternal grandmother. PLoS One 2011: 6: e24101.
60. Strober S, Spitzer TR, Lowsky R, Sykes M. Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction. Semin Immunol 2011: 23: 273-81.
61. Mold JE, Michaëlsson J, Burt TD et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 2008: 322: 1562-5.
62. van Rood JJ, Scaradavou A, Stevens CE. Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. Proc Natl Acad Sci U S A 2012: 109: 2509-14.
63. Pilat N, Wekerle T. Combining Treg therapy with mixed chimerism: Getting the best of both worlds. Chimerism 2010: 1: 26-9.
64. Scandling JD, Busque S, Dejbakhsh-Jones S et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008: 358: 362-8.
65. Roselli EA, Mezzadra R, Frittoli MC et al. Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med 2010: 2: 315-28.
66. Roncarolo MG, Yssel H, Touraine JL, Betuel H, De Vries JE, Spits H. Autoreactive T cell clones specific for class I and class II HLA antigens isolated from a human chimera. J Exp Med 1988: 167: 1523-34.
67. Bacchetta R, Bigler M, Touraine JL et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994: 179: 493-502.
68. Gregori S, Roncarolo MG, Bacchetta R. Methods for in vitro generation of human type 1 regulatory T cells. Methods Mol Biol 2011: 677: 31-46.
69. Serafini G, Andreani M, Testi M et al. Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica 2009: 94: 1415-26.
70. Magnani CF, Alberigo G, Bacchetta R et al. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol 2011: 41: 1652-62.
71. Gagliani N, Magnani CF, Huber S et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 2013: 19: 739-46.
72. Tang Q, Bluestone JA, Kang SM. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol 2012: 4: 11-21.
73. Roncarolo MG, Gregori S, Lucarelli B, Ciceri F. Bacchetta R Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol Rev 2011: 241: 145-63.